01:01 GMT21 September 2020
Listen Live
    Get short URL

    New Delhi (Sputnik): India imports almost 70 percent of the raw materials for drug manufacturing from China. Data from the Directorate General of Commercial Intelligence and Statistics reveals that India imported bulk drugs and intermediates worth $2,738 million in 2016-2017 and $2,993 million in 2017-18.

    While the Indian and Chinese armies recently engaged in a face off on the Line of Actual Control (LAC), Chinese suppliers have raised the price of medical supplies to India despite the ongoing COVID-19 pandemic.   

    The hike can be seen in the prices of active pharmaceutical ingredients (APIs), key starting materials (KSMs), and other drug intermediaries, which has the potential to impact the Indian pharmaceutical industry.

    "On an average, the increase in the prices of APIs and KSMs has been around 20 percent compared to the pre-COVID-19 days", says Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, a representative body of leading Indian pharmaceutical companies. 

    According the pharmaceutical body, there has been a 100 percent increase in the price of isopropyl alcohol imported from China. Para amino phenol, a key material in the manufacture of paracetamol, has seen a 27 percent price hike.

    India imports 70% of the active pharmaceutical ingredients (APIs) from China. These are the basic building blocks, or raw materials, of medicine.

    With the imported APIs, India manufactures key medicines such as paracetamol, metformin, among others, that are used domestically as well as exported to the world market.



    India Begins Clinical Trial of New Drug to Save Lives for Critically-Ill COVID-19 Patients
    COVID-19: India Approves Clinical Trials of Japanese Flu Drug Favipiravir
    Top Indian Scientist Condemns WHO's "Knee-Jerk" Move to Suspend Trial of Malaria Drug for COVID-19
    COVID-19, medicine, drug, India
    Community standardsDiscussion